CEL-SCI Corporation announced consolidated financial result for the year ended September 30, 2013. The company reported an operating loss of $19.87 million in fiscal year 2013 versus an operating loss of $17.24 million in fiscal year 2012. The rise in operating loss was partially attributable to an increase in research and development expenses to $12.68 million in fiscal year 2013 compared to $10.37 million in fiscal year 2012.

The net loss available to common shareholders for the fiscal year 2013 was $9.23 million, or $0.30 per diluted share, versus a loss of $17.65 million, or $0.70 per diluted share for the fiscal year 2012. The change in net loss available to common shareholders in fiscal year 2013 was primarily due to the gain on derivative instruments of $10.75 million for fiscal year 2013 versus a gain on derivative instruments of $1.91 million for fiscal year 2012. Grant income and other was $159,583 against $254,610 a year ago.